HOME >> MEDICINE >> NEWS
Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., South San Francisco, Calif., which manufactures bevacizumab, provided bevacizumab for the trial under the Cooperative Research and Development Agreement (CRADA) with NCI for the clinical development of bevacizumab.

The Data Monitoring Committee overseeing the trial (known as E4599)* recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of improving overall survival. Researchers found that patients in the study who received bevacizumab in combination with standard chemotherapy (a treatment regimen of paclitaxel and carboplatin) had a median overall survival of 12.5 months compared to patients treated with the standard chemotherapy alone, who had a median survival of 10.2 months. This difference is statistically significant. Detailed results from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) to be held in Orlando, Fla., on May 13-17, 2005.

"The exciting results of this randomized study reveal, for the first time, an improvement in survival with the addition of a targeted agent to standard chemotherapy in this patient population," said Study Chair Alan B. Sandler, M.D., of the Vanderbilt University Medical Center in Nashville, Tenn.

"This study demonstrates that mechanistic-based interventions such as angiogenesis inhibitors are making important contribution
'"/>

Contact: NCI Press Officers
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
14-Mar-2005


Page: 1 2 3

Related medicine news :

1. Tuberculosis drug combined with virtual reality therapy is effective in treating fear of heights
2. Detrol LA combined with standard treatment for enlarged prostate is twice as effective
3. Nicotine more addictive when combined with other tobacco smoke chemicals, UCI study finds
4. Cognitive behavioral therapy combined with antidepressant effective in treating adolescent OCD
5. Heart disease kills more women annually than all cancers combined
6. Stents combined with clot-busting drugs effective in limiting impact of deadly form of stroke
7. Study shows people with Alzheimers can benefit from exercise combined with caregiver training
8. Wyeth chemists honored for Prevnar first combined pneumococcal vaccine for infants
9. Task force issues caution on combined hormone therapy
10. University of Pittsburgh research shows combined PET/CT finds cancerous lesions standard CT misses
11. Some patients are candidates for combined heart bypass, lung transplant surgeries

Post Your Comments:
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... Omaha, NE (PRWEB) March 27, 2015 Ticket ... tickets at the CenturyLink Center in Omaha, Nebraska on ... a possibility that more concert dates will be added in ... result of fan demand. , The Garth Brooks World Tour ... with the latest announcement that Garth Brooks and Trisha Yearwood ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 DrugDev announced ... (Liss) Easy was named to the 2015 Philadelphia Business ... 40 list spotlights 40 dynamic, up-and-coming leaders less than ... community involvement. Winners are honored at an awards program ... the Philadelphia Business Journal. , Lyn Kremer, Publisher of ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Endure ... Yoga for functional fitness athletes. This new program matches ... specific protocol for post-workout cool down. This program utilizes ... breath control and mental focus. , Karen Lefurgy, ... started practicing yoga long before I started Crossfit® training, ...
(Date:3/27/2015)... According to Health Day , on March ... Syndrome (NAS) are causing alarm for Florida officials. Infants ... for a month of their lives- and can experience ... The condition is precipitated by drug use during pregnancy. ... employing medically assisted drug treatment) will also inflict NAS ...
Breaking Medicine News(10 mins):Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2
(Date:3/27/2015)... 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ) ... appointed to the Company,s Board of Directors effective March 23, ... November 2014 of board member Joseph Barton .  ... our Board of Directors represents an important step forward for ... president of Dynatronics.  "Rich is a proven leader and is ...
(Date:3/27/2015)... March 27, 2015 Biopharmaceutical Industry Leads ... industry comes out on top as the country,s manufacturing ... new report  from ndp│analytics. According to the  analysis , ... investment over the last decade, accounting for 27 percent ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... , March 27, 2015   Cypher Genomics, ... announced new data showing that, compared to a ... technology provided highly equivalent interpretations of whether certain ... did so in a fraction of the time. ... for more comprehensive genetic analysis in non-invasive prenatal ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
Cached News: